<div id="readability-page-1"><div><ul> <li>Vaxart, Inc. recently reported in npj Vaccines that its double-blind, placebo-controlled Phase 1 trial of a single-dose oral bivalent norovirus vaccine in breastfeeding women showed vaccine-induced functional norovirus-specific antibodies in maternal breastmilk and serum, as well as norovirus-specific IgA in the stool of their breastfed infants, with the vaccine remaining safe and well tolerated.</li> <li>The finding of a positive correlation between breast milk IgA levels and infant stool IgA offers early evidence that an oral maternal vaccine might help confer immune protection to infants against a virus for which no approved vaccines currently exist.</li> <li>We will now examine how this early evidence of passive infant protection from an oral norovirus vaccine could shape Vaxart’s investment narrative.</li> </ul><p>Uncover the next big thing with financially sound penny stocks that balance risk and reward.</p><h2>What Is Vaxart's Investment Narrative?</h2><p>To own Vaxart today, you have to believe its oral vaccine platform can convert promising early data into funded, late‑stage programs despite a difficult history of losses and volatility. The new npj Vaccines publication on the norovirus candidate adds a credible scientific win, showing signals of passive infant protection and reinforcing the idea that an oral approach might matter clinically, not just conceptually. In the near term, though, the more immediate value drivers still look like funding, partnerships and regulatory progress in norovirus and the BARDA‑supported COVID‑19 program, especially after the move off Nasdaq and the small follow‑on offering. The norovirus data could marginally improve Vaxart’s case in future partnering talks, but it does not remove key risks around cash burn, expected revenue contraction and execution.</p><p> However, one funding and listing risk in particular is easy to overlook and hard to ignore.  Our expertly prepared valuation report on Vaxart implies its share price may be too high.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8eb6e44b-1617-4cdd-977b-cdef90866846/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8eb6e44b-1617-4cdd-977b-cdef90866846/chart/quote-price"/><figcaption>VXRT 1-Year Stock Price Chart</figcaption></figure><p> The Simply Wall St Community’s 11 fair value estimates span roughly US$1.12 to US$11.20 per share, showing how differently people view Vaxart’s prospects. Set that wide spread against the company’s ongoing losses and funding needs and you can see why opinions diverge so much. You are better off weighing several of these views before deciding how Vaxart’s clinical and financing risks might affect its long term potential.</p><p>Explore 11 other fair value estimates on Vaxart - why the stock might be worth just $1.12!</p><h2>Build Your Own Vaxart Narrative</h2><p>Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Vaxart research is our analysis highlighting 3 important warning signs that could impact your investment decision.</li><li>Our free Vaxart research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vaxart's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:</p><ul><li>The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</li><li>Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.</li><li>AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

<p>Vaxart, Inc. has reported promising results from its Phase 1 trial of an oral bivalent norovirus vaccine, showing immune responses in breastfeeding women and their infants. This early data suggests potential passive protection for infants, which could enhance Vaxart's investment narrative. However, the company faces challenges including cash burn and funding needs, with stock valuations varying widely among analysts. The findings may improve Vaxart's position in future partnerships, but significant risks remain regarding its financial health and operational execution.</p>

Simplywall

Health Care Select Sector SPDR

VG Health

iShares US Pharma

VanEck Biotech ETF

iShares Global Healthcare

Vaxart

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Does Vaxart’s (VXRT) Early Norovirus Infant Data Hint At A Broader Oral Vaccine Platform Advantage?